Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mutant p53: the loaded gun.

G Selivanova1

  • 1Cancer Center Karolinska (CCK), Karolinska Institute, Stockholm, Sweden. Galina.Selivanova@mtc.ki.se

Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
PubMed
Summary

Mutations in the p53 gene are common in tumors. This review explores strategies to reactivate mutant p53 for targeted cancer therapy, potentially offering a novel, non-toxic treatment approach.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The conserved Trp114 residue of thioredoxin reductase 1 has a redox sensor-like function triggering oligomerization and crosslinking upon oxidative stress related to cell death.

Cell death & disease·2015
Same author

Pharmacological reactivation of p53 as a strategy to treat cancer.

Journal of internal medicine·2014
Same author

Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosis.

Cell death and differentiation·2014
Same author

ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis.

Cell death and differentiation·2014
Same author

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.

Cell death & disease·2013
Same author

Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis.

Cell death and differentiation·2012

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • TP53 gene alterations are the most frequent genetic defects in human tumors.
  • p53 protein is a crucial inducer of cell death, and its inactivation is nearly universal in tumor development.
  • Mutant p53 proteins accumulate to high levels within tumor cells.

Purpose of the Study:

  • To investigate the potential of exploiting p53 mutations for selective tumor cell killing.
  • To explore novel, non-toxic anticancer therapeutic strategies targeting p53.
  • To review current approaches for reactivating mutant p53 in tumors.

Main Methods:

  • Review of existing literature on p53 gene mutations in cancer.
  • Analysis of the characteristics of p53 inactivation in tumors.
  • Exploration of therapeutic strategies targeting mutant p53.

Main Results:

  • Approximately 50% of human tumors harbor p53 mutations.
  • 87% of these mutations are missense point mutations within the DNA-binding domain.
  • Mutant p53 proteins are overexpressed in tumor cells.

Conclusions:

  • The high frequency and specific nature of p53 mutations present a potential therapeutic vulnerability.
  • Reactivating mutant p53 could offer a selective and non-toxic approach to cancer treatment.
  • Further research into p53 reactivation strategies is warranted for novel anticancer therapies.

Related Experiment Videos